|
|
Vaccine Detail
|
V-01 |
| Vaccine Information |
- Vaccine Name: V-01
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Livzon Mabpharm Inc.
- Vaccine Ontology ID: VO_0005247
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Immune Response: A dramatic increase (11.3-fold; 128.3-1452.8) of neutralizing titres was measured in the V-01 group at 14 days after the booster. Over two months of surveillance, vaccine efficacy was 47.8% (95%CI: 22.6-64.7) according to the intention-to-treat principle. (Wang et al. 2022)
- Side Effects: The most common adverse events were transient, mild-to-moderate pain at the injection site, fever, headache, and fatigue. (Wang et al. 2022)
|
| References |
Wang et al. 2022: Xuan-Yi Wang 1 2 3, Syed Faisal Mahmood 4, Fang Jin 5 6, Wee Kooi Cheah 7, Muhammad Ahmad 8, Mian Amjad Sohail 9, Waheed Ahmad 10, Vijaya K Suppan 11, Muneeba Ahsan Sayeed 12, Shobha Luxmi 13, Aik-Howe Teo 14, Li Yuan Lee 15, Yang-Yang Qi 1 2, Rong-Juan Pei 16, Wei Deng 6, Zhong-Hui Xu 17, Jia-Ming Yang 17, Yan Zhang 17, Wu-Xiang Guan 16, Xiong Yu 18. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. . 2022; ; . [PubMed: 35686572].
|
|
